Clenbuterol

Routes
Oral (PO)
Half-Life (t½)
PO: 35h
Formula
C12H18Cl2N2O
Molecular Weight
277.19 g/mol
PubChem CID
2783
Aliases
Clen

Pharmacological Mechanism

Long-acting selective β2-adrenergic receptor agonist (Gs/cAMP). Bronchodilator (approved abroad, not for human use in the US). Abused off-label for fat loss via β2-mediated lipolysis, thermogenesis, and a repartitioning/mild anabolic effect on skeletal muscle. Adverse effects: tachycardia, tremor, hypokalemia, and cardiac hypertrophy/arrhythmia risk; the long half-life prolongs toxicity.

Half-Life & Elimination Curve (PO: 35h)

100%50%25%12.5%0%0h0×t½35h1×t½70h2×t½4.4d3×t½5.8d4×t½7.3d5×t½0×t½ (0h): 100% remaining1×t½ (35h): 50% remaining2×t½ (70h): 25% remaining3×t½ (4.4d): 12.5% remaining4×t½ (5.8d): 6.3% remaining5×t½ (7.3d): 3.1% remaining
Plasma (PO)t½ Decay (35h)
  • 0×t½0h100%
  • 1×t½35h50%
  • 2×t½70h25%
  • 3×t½4.4d12.5%
  • 4×t½5.8d6.3%
  • 5×t½7.3d3.1%
Elimination t½35h (PO)
Rate Constant (ke)0.0198 h⁻¹
Time to Peak (Tmax)2.5h
97% Washout (5×t½)7.3d

Dosing Guidelines

Pharmacokinetic Parameters

Target Organ Systems

Notes

PubChem CID 2783 (free base). NOT a steroid — a β2-agonist. Doses are in MICROGRAMS (20–120 µg/day). PK: Yamamoto 1985 (PMID:4045696) verbatim "The half-life of clenbuterol in plasma was estimated to be about 35 h" in man after oral clenbuterol HCl.

Chemical Structure & Identifiers

References